Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBPNASDAQ:GRTXOTCMKTS:INVVYNASDAQ:REPHNASDAQ:VRCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$37.74+0.1%$35.88$3.03▼$49.87$396.65M2.45795,268 shs500,504 shsGRTXGalera Therapeutics$0.19$0.20$0.09▼$3.59$10.55M2.172.39 million shs352,721 shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shsVRCAVerrica Pharmaceuticals$6.85+0.9%$5.72$2.86▼$7.76$290.58M1.88158,575 shs86,259 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-3.92%-11.75%+7.90%+416.44%+326.47%GRTXGalera Therapeutics+3.70%+24.79%-18.46%+6.12%-93.16%INVVYIndivior0.00%0.00%0.00%0.00%+0.30%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%VRCAVerrica Pharmaceuticals-2.72%-1.88%+35.53%+17.07%+4.30%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.4921 of 5 stars3.53.00.04.72.93.30.6GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.5837 of 5 stars3.51.00.04.70.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals3.00Buy$52.0037.78% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/AINVVYIndiviorN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.00Buy$11.2564.23% UpsideCurrent Analyst RatingsLatest VRCA, CRBP, REPH, INVVY, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus Pharmaceuticals$880K450.74N/AN/A($1.56) per share-24.19GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AINVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00VRCAVerrica Pharmaceuticals$5.12M56.75N/AN/A$0.47 per share14.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/AVRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)Latest VRCA, CRBP, REPH, INVVY, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A0.740.74GRTXGalera TherapeuticsN/A4.364.36INVVYIndiviorN/AN/AN/AREPHRecro Pharma2.273.242.74VRCAVerrica Pharmaceuticals2.224.554.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%GRTXGalera Therapeutics50.77%INVVYIndivior0.05%REPHRecro Pharma62.34%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%GRTXGalera Therapeutics6.90%INVVYIndiviorN/AREPHRecro Pharma14.20%VRCAVerrica Pharmaceuticals41.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableGRTXGalera Therapeutics754.39 million50.64 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionableVRCAVerrica Pharmaceuticals10042.42 million24.82 millionOptionableVRCA, CRBP, REPH, INVVY, and GRTX HeadlinesSourceHeadlineVerrica Pharmaceuticals Inc (VRCA)investing.com - April 19 at 7:13 PMNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)marketbeat.com - April 10 at 8:24 AMVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conferencemsn.com - April 4 at 11:15 AMStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossfinance.yahoo.com - April 3 at 8:23 AMVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protectionmsn.com - March 31 at 11:37 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAfinanznachrichten.de - March 28 at 3:45 PMVerrica Pharma gains as FDA lists Ycanth in Orange Bookmsn.com - March 27 at 3:42 AMVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Factsmarkets.businessinsider.com - March 26 at 8:15 AMVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAglobenewswire.com - March 26 at 7:30 AMVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chatmsn.com - March 3 at 10:22 PMVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 2 at 10:39 AMWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?finance.yahoo.com - March 2 at 10:39 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 11:46 PMVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Ratingmarkets.businessinsider.com - March 1 at 6:46 PMBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansionmarkets.businessinsider.com - March 1 at 6:46 PMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:45 PMBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptancemarkets.businessinsider.com - February 29 at 10:09 PMVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 12:07 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - February 29 at 7:30 AMEarnings Outlook For Verrica Pharmaceuticalsbenzinga.com - February 28 at 6:01 PMVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:30 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024finance.yahoo.com - February 22 at 10:58 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024globenewswire.com - February 22 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.